Skip to content


The Alnitak program is developing first-in-class oral, small molecule, potent and selective inhibitors of TAK1.

TAK1 is a serine/threonine kinase that acts as a central regulator of inflammatory signaling pathways that integrates innate immune signalling and NLRP3 inflammasome activation. Clinically validated pathways/mediators such as IL-6, TNFɑ and IL-1β are directly linked to TAK1 activity. An oral selective TAK1 inhibitor has the potential to treat a wide range of inflammatory and autoimmune diseases, including rheumatoid arthritis, gout, inflammatory bowel disease and fibrosis.

Using cutting edge expertise in structure-based drug discovery (SBDD) and pharmacology, Aqilion has within the Alnitak program discovered highly potent and drug-like TAK1 inhibitors. Aqilion will nominate a candidate for preclinical development in 2022.